Identification

Name
Voxilaprevir
Accession Number
DB12026
Type
Small Molecule
Groups
Approved
Description

Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [3].

Voxilaprevir exerts its antiviral action by reversibley binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label]. Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B [2]. By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as voxilaprevir.

Voxilaprevir has been available since July 2017 in a fixed dose combination product with Sofosbuvir and Velpatasvir as the commercially available product Vosevi. Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label]. Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor [4]. Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection.

Structure
Thumb
Synonyms
Not Available
External IDs
GS 9857 / GS-9857 / GS9857
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
VoseviVoxilaprevir (100 mg/1) + Sofosbuvir (400 mg/1) + Velpatasvir (100 mg/1)Tablet, film coatedOralGilead Sciences2017-07-18Not applicableUs
VoseviVoxilaprevir (100 mg) + Sofosbuvir (400 mg) + Velpatasvir (100 mg)TabletOralGilead Sciences2017-09-18Not applicableCanada
Categories
UNII
0570F37359
CAS number
1535212-07-7
Weight
Average: 868.94
Monoisotopic: 868.345261104
Chemical Formula
C40H52F4N6O9S
InChI Key
MZBLZLWXUBZHSL-FZNJKFJKSA-N
InChI
InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
IUPAC Name
(1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0^{3,12}.0^{5,10}.0^{18,20}]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide
SMILES
CC[[email protected]@H]1[[email protected]@H]2CN([[email protected]@H]1C(=O)N[[email protected]@]1(C[[email protected]]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[[email protected]@H](NC(=O)O[[email protected]@H]1C[[email protected]]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C

Pharmacology

Indication

Vosevi (Voxilaprevir/Sofosbuvir/Velpatasvir) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor [4].

Structured Indications
Not Available
Pharmacodynamics

Voxilaprevir is a direct-acting antiviral agent that targets viral NS3/4A protein and causes a decrease in serum HCV RNA levels. It disrupts HCV replication by specifically inhibiting the critical functions of NS3/4A protein in the replication complex. It does not appear to prolong the QT interval even when given at 9 times the maximum recommended dose [FDA Label].

Mechanism of action

Voxilaprevir exerts its antiviral action by reversibley binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label]. Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B [2]. By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function.

TargetActionsOrganism
ANS3/4A protein
inhibitor
Hepatitis C virus
Absorption

When provided as the fixed dose combination product Vosevi with Sofosbuvir and Velpatasvir, voxilaprevir reaches a maximum concentration (Cmax) of 192 ng/mL at a maximum time (Tmax) of 4 hours post-dose [FDA Label].

Volume of distribution
Not Available
Protein binding

Voxilaprevir is more than 99% bound to human plasma proteins [FDA Label].

Metabolism

Voxilaprevir is primarily metabolized by Cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2C8 and CYP1A2[FDA Label].

Route of elimination

Voxilaprevir is primarily eliminated via biliary excretion [FDA Label].

Half life

33 hr [FDA Label]

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Hepatitis C Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Voxilaprevir can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Voxilaprevir.Approved
AcetaminophenThe serum concentration of Voxilaprevir can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Voxilaprevir.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Voxilaprevir.Approved
AlbendazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Voxilaprevir can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Voxilaprevir can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Voxilaprevir can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Voxilaprevir.Approved, Investigational
AmantadineThe serum concentration of Voxilaprevir can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Voxilaprevir.Approved, Investigational
Aminohippuric acidThe serum concentration of Voxilaprevir can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Voxilaprevir can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Voxilaprevir can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Voxilaprevir can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Voxilaprevir can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Voxilaprevir can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Voxilaprevir.Approved
AprepitantThe serum concentration of Voxilaprevir can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Voxilaprevir.Approved, Investigational
AstemizoleThe serum concentration of Voxilaprevir can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Voxilaprevir can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Voxilaprevir can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Voxilaprevir can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Voxilaprevir can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Voxilaprevir.Approved, Investigational
AzelastineThe serum concentration of Voxilaprevir can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Voxilaprevir can be increased when it is combined with Azithromycin.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Voxilaprevir.Approved, Investigational
BenzocaineThe serum concentration of Voxilaprevir can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Voxilaprevir can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Voxilaprevir.Approved, Vet Approved
BiperidenThe serum concentration of Voxilaprevir can be increased when it is combined with Biperiden.Approved
BoceprevirThe metabolism of Voxilaprevir can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Voxilaprevir can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Voxilaprevir can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Voxilaprevir.Approved
BromocriptineThe serum concentration of Voxilaprevir can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Voxilaprevir can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Voxilaprevir can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Voxilaprevir can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Voxilaprevir can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Voxilaprevir.Experimental
CanagliflozinThe serum concentration of Voxilaprevir can be increased when it is combined with Canagliflozin.Approved
Candesartan cilexetilThe serum concentration of Voxilaprevir can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Voxilaprevir can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Voxilaprevir can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Voxilaprevir.Approved
CarvedilolThe serum concentration of Voxilaprevir can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Voxilaprevir can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Voxilaprevir can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Voxilaprevir can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Voxilaprevir.Withdrawn
ChloroquineThe serum concentration of Voxilaprevir can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Voxilaprevir can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Voxilaprevir can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Voxilaprevir can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Voxilaprevir can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Voxilaprevir can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Voxilaprevir can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Voxilaprevir can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Voxilaprevir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Voxilaprevir.Approved
CitalopramThe serum concentration of Voxilaprevir can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Voxilaprevir can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Voxilaprevir can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Voxilaprevir.Approved, Illicit
ClofazimineThe serum concentration of Voxilaprevir can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Voxilaprevir.Approved, Investigational
ClomipramineThe serum concentration of Voxilaprevir can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Voxilaprevir.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Voxilaprevir.Approved, Nutraceutical
ClotrimazoleThe metabolism of Voxilaprevir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Voxilaprevir.Approved
CobicistatThe metabolism of Voxilaprevir can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Voxilaprevir.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Voxilaprevir.Approved
ColforsinThe serum concentration of Voxilaprevir can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Voxilaprevir can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Voxilaprevir.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Voxilaprevir.Approved
CrisaboroleThe metabolism of Voxilaprevir can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Voxilaprevir can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Voxilaprevir can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Voxilaprevir can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Voxilaprevir can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Voxilaprevir.Approved
DabrafenibThe serum concentration of Voxilaprevir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Voxilaprevir can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Voxilaprevir can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Voxilaprevir.Approved
DarunavirThe metabolism of Voxilaprevir can be decreased when combined with Darunavir.Approved
DaunorubicinThe serum concentration of Voxilaprevir can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Voxilaprevir.Approved
DeferasiroxThe serum concentration of Voxilaprevir can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Voxilaprevir can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Voxilaprevir can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Voxilaprevir can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Voxilaprevir can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Voxilaprevir can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Voxilaprevir.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Voxilaprevir can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Voxilaprevir.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Voxilaprevir.Approved
DigoxinThe serum concentration of Voxilaprevir can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Voxilaprevir can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Voxilaprevir.Illicit
DiltiazemThe metabolism of Voxilaprevir can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Voxilaprevir can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Voxilaprevir.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Voxilaprevir.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Voxilaprevir can be decreased when combined with Dosulepin.Approved
DoxazosinThe serum concentration of Voxilaprevir can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Voxilaprevir can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Voxilaprevir.Approved, Investigational
DoxorubicinThe serum concentration of Voxilaprevir can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Voxilaprevir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Voxilaprevir can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Voxilaprevir can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Voxilaprevir.Approved
EfavirenzThe metabolism of Voxilaprevir can be decreased when combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Voxilaprevir can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Voxilaprevir.Approved, Investigational
EltrombopagThe serum concentration of Voxilaprevir can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Voxilaprevir can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Voxilaprevir.Approved
EnzalutamideThe serum concentration of Voxilaprevir can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Voxilaprevir.Approved, Investigational
ErgonovineThe serum concentration of Voxilaprevir can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Voxilaprevir can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Voxilaprevir.Approved, Investigational
ErythromycinThe metabolism of Voxilaprevir can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Voxilaprevir.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Voxilaprevir can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Voxilaprevir can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Voxilaprevir can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Voxilaprevir.Approved
EtoposideThe serum concentration of Voxilaprevir can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Voxilaprevir can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Voxilaprevir.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Voxilaprevir.Approved
FelodipineThe serum concentration of Voxilaprevir can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Voxilaprevir can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Voxilaprevir.Approved
FexofenadineThe serum concentration of Voxilaprevir can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Voxilaprevir can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe metabolism of Voxilaprevir can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of Voxilaprevir can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Voxilaprevir can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Voxilaprevir can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Voxilaprevir can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Voxilaprevir.Approved
FluvoxamineThe metabolism of Voxilaprevir can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Voxilaprevir can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Voxilaprevir can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Voxilaprevir can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Voxilaprevir can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Voxilaprevir can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Voxilaprevir.Approved
GenisteinThe serum concentration of Voxilaprevir can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Voxilaprevir.Approved
GlyburideThe serum concentration of Voxilaprevir can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Voxilaprevir can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Voxilaprevir can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Voxilaprevir.Approved
GrepafloxacinThe serum concentration of Voxilaprevir can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Voxilaprevir can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Voxilaprevir can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Voxilaprevir.Approved
IdelalisibThe serum concentration of Voxilaprevir can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Voxilaprevir can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Voxilaprevir can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Voxilaprevir.Approved
IndinavirThe metabolism of Voxilaprevir can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Voxilaprevir can be increased when it is combined with Indomethacin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Voxilaprevir.Approved
IrbesartanThe metabolism of Voxilaprevir can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Voxilaprevir.Approved, Investigational
IsavuconazoniumThe metabolism of Voxilaprevir can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Voxilaprevir can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Voxilaprevir can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Voxilaprevir can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Voxilaprevir can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Voxilaprevir can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Voxilaprevir.Approved
KetoconazoleThe metabolism of Voxilaprevir can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Voxilaprevir.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Voxilaprevir.Approved, Investigational
LansoprazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Voxilaprevir can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Voxilaprevir.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Voxilaprevir.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Voxilaprevir.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Voxilaprevir.Approved, Investigational
LevofloxacinThe serum concentration of Voxilaprevir can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Voxilaprevir.Approved
LevothyroxineThe serum concentration of Voxilaprevir can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Voxilaprevir can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Voxilaprevir.Approved
LiothyronineThe serum concentration of Voxilaprevir can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Voxilaprevir can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Voxilaprevir can be increased when it is combined with Lisinopril.Approved, Investigational
LobeglitazoneThe metabolism of Voxilaprevir can be decreased when combined with Lobeglitazone.Approved
LomitapideThe serum concentration of Voxilaprevir can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Voxilaprevir can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Voxilaprevir can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Voxilaprevir can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Voxilaprevir can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Voxilaprevir can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Voxilaprevir can be increased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Voxilaprevir.Approved, Investigational
MaprotilineThe serum concentration of Voxilaprevir can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Voxilaprevir can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Voxilaprevir can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Voxilaprevir can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Voxilaprevir can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Voxilaprevir.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Voxilaprevir.Approved, Vet Approved
MetoprololThe serum concentration of Voxilaprevir can be increased when it is combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Voxilaprevir can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Voxilaprevir can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Voxilaprevir can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Voxilaprevir can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Voxilaprevir can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Voxilaprevir.Approved
MitomycinThe serum concentration of Voxilaprevir can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Voxilaprevir can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Voxilaprevir can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Voxilaprevir can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Voxilaprevir.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Voxilaprevir.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Voxilaprevir.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Voxilaprevir.Approved, Vet Approved
NaltrexoneThe serum concentration of Voxilaprevir can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Voxilaprevir can be increased when it is combined with Naringenin.Experimental
NefazodoneThe metabolism of Voxilaprevir can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Voxilaprevir can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Voxilaprevir can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Voxilaprevir can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Voxilaprevir can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Voxilaprevir can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Voxilaprevir can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Voxilaprevir can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Voxilaprevir.Approved
NisoldipineThe serum concentration of Voxilaprevir can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Voxilaprevir can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Voxilaprevir can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Voxilaprevir.Approved
NorethisteroneThe serum concentration of Voxilaprevir can be decreased when it is combined with Norethisterone.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Voxilaprevir.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Voxilaprevir.Approved, Investigational
OlaparibThe metabolism of Voxilaprevir can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Voxilaprevir.Approved
OmeprazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Voxilaprevir can be increased when it is combined with Osimertinib.Approved
P-NitrophenolThe serum concentration of Voxilaprevir can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Voxilaprevir can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Voxilaprevir can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Voxilaprevir can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Voxilaprevir.Approved, Investigational
PantoprazoleThe serum concentration of Voxilaprevir can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Voxilaprevir can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Voxilaprevir.Approved
Peginterferon alfa-2bThe serum concentration of Voxilaprevir can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Voxilaprevir can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Voxilaprevir can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Voxilaprevir can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Voxilaprevir can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Voxilaprevir.Approved
PimozideThe serum concentration of Voxilaprevir can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Voxilaprevir can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Voxilaprevir.Approved
Platelet Activating FactorThe serum concentration of Voxilaprevir can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Voxilaprevir.Approved
PonatinibThe serum concentration of Voxilaprevir can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Voxilaprevir can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Voxilaprevir can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Voxilaprevir can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Voxilaprevir.Approved, Vet Approved
PrednisoneThe serum concentration of Voxilaprevir can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Voxilaprevir can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Voxilaprevir can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Voxilaprevir can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Voxilaprevir can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Voxilaprevir can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Voxilaprevir can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Voxilaprevir can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Voxilaprevir.Approved
QuercetinThe serum concentration of Voxilaprevir can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Voxilaprevir.Approved
QuinacrineThe serum concentration of Voxilaprevir can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Voxilaprevir can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Voxilaprevir can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Voxilaprevir can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Voxilaprevir can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Voxilaprevir.Approved, Investigational
ReboxetineThe serum concentration of Voxilaprevir can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Voxilaprevir can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Voxilaprevir can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Voxilaprevir can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Voxilaprevir can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Voxilaprevir can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Voxilaprevir.Approved, Investigational
RilpivirineThe serum concentration of Voxilaprevir can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Voxilaprevir.Approved, Investigational
RitonavirThe metabolism of Voxilaprevir can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Voxilaprevir.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Voxilaprevir.Approved, Investigational
RopiniroleThe metabolism of Voxilaprevir can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Voxilaprevir can be decreased when combined with Rosiglitazone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Voxilaprevir.Approved, Vet Approved
SaquinavirThe metabolism of Voxilaprevir can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Voxilaprevir can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Voxilaprevir can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Voxilaprevir can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Voxilaprevir.Approved
SertralineThe serum concentration of Voxilaprevir can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Voxilaprevir can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Voxilaprevir.Approved
SiltuximabThe serum concentration of Voxilaprevir can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Voxilaprevir can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Voxilaprevir can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Voxilaprevir.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Voxilaprevir.Approved
SorafenibThe serum concentration of Voxilaprevir can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Voxilaprevir.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Voxilaprevir.Experimental
SpironolactoneThe serum concentration of Voxilaprevir can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Voxilaprevir can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Voxilaprevir can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Voxilaprevir can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Voxilaprevir can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleThe metabolism of Voxilaprevir can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Voxilaprevir can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Voxilaprevir can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Voxilaprevir can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Voxilaprevir can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Voxilaprevir can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Voxilaprevir can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Voxilaprevir can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Voxilaprevir can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Voxilaprevir.Approved
TelaprevirThe metabolism of Voxilaprevir can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Voxilaprevir can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Voxilaprevir can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Voxilaprevir can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe metabolism of Voxilaprevir can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe serum concentration of Voxilaprevir can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Voxilaprevir can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Voxilaprevir can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Voxilaprevir can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Voxilaprevir can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe metabolism of Voxilaprevir can be decreased when combined with Theophylline.Approved
TicagrelorThe serum concentration of Voxilaprevir can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Voxilaprevir can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Voxilaprevir.Approved
TocilizumabThe serum concentration of Voxilaprevir can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Voxilaprevir can be increased when it is combined with Tolvaptan.Approved
TopiroxostatThe metabolism of Voxilaprevir can be decreased when combined with Topiroxostat.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Voxilaprevir.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Voxilaprevir.Approved
TrazodoneThe serum concentration of Voxilaprevir can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Voxilaprevir can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Voxilaprevir can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Voxilaprevir can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Voxilaprevir can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Voxilaprevir can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Voxilaprevir.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Voxilaprevir.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Voxilaprevir.Approved
VelpatasvirThe serum concentration of Voxilaprevir can be increased when it is combined with Velpatasvir.Approved
VemurafenibThe serum concentration of Voxilaprevir can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Voxilaprevir.Approved
VenlafaxineThe metabolism of Voxilaprevir can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Voxilaprevir can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Voxilaprevir can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Voxilaprevir.Approved, Investigational
VincristineThe serum concentration of Voxilaprevir can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Voxilaprevir can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Voxilaprevir.Approved
VoriconazoleThe metabolism of Voxilaprevir can be decreased when combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Voxilaprevir.Approved
ZimelidineThe serum concentration of Voxilaprevir can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Voxilaprevir can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Voxilaprevir can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
  1. Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Ledinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S: Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512. [PubMed:28564569]
  2. Moradpour D, Penin F: Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113-42. doi: 10.1007/978-3-642-27340-7_5. [PubMed:23463199]
  3. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
  4. FDA News Release: FDA approves Vosevi for Hepatitis C [Link]
External Links
ChemSpider
44209500
ChEMBL
CHEMBL3707372
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Voxilaprevir
AHFS Codes
  • 08:18.40.16 — HCV Polymerase Inhibitors
FDA label
Download (1.34 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHCV Infections3
1CompletedTreatmentHepatitis C Virus Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentHepatitis C Virus Infection3
2RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection1
3Active Not RecruitingTreatmentHepatitis C Virus Infection1
3CompletedTreatmentChronic Hepatitis C Infection2
3CompletedTreatmentHepatitis C Virus Infection2
4RecruitingTreatmentHCV Coinfection / Human Immunodeficiency Virus (HIV) / Liver Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7964580No2009-03-262029-03-26Us
US8334270No2008-03-212028-03-21Us
US8633309No2009-03-262029-03-26Us
US8618076No2010-12-112030-12-11Us
US8735372No2008-03-212028-03-21Us
US8580765No2008-03-212028-03-21Us
US8889159No2009-03-262029-03-26Us
US9085573No2008-03-212028-03-21Us
US9284342No2010-09-132030-09-13Us
US8940718No2012-11-162032-11-16Us
US8575135No2012-11-162032-11-16Us
US8921341No2012-11-162032-11-16Us
US9585906No2008-03-212028-03-21Us
US9296782No2014-07-172034-07-17Us

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0506 mg/mLALOGPS
logP3.98ALOGPS
logP4.9ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.74ChemAxon
pKa (Strongest Basic)-0.84ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area195.22 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity203.02 m3·mol-1ChemAxon
Polarizability85.37 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Cyclic peptides
Alternative Parents
Macrolactams / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Quinoxalines / Pyrrolidinecarboxamides / Anisoles / Alkyl aryl ethers / Pyrazines / Cyclopropanecarboxylic acids and derivatives / Tertiary carboxylic acid amides
show 15 more
Substituents
Cyclic alpha peptide / Macrolactam / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Diazanaphthalene / Alpha-amino acid or derivatives / Quinoxaline / Anisole / Phenol ether / Pyrrolidine carboxylic acid or derivatives
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Hepatitis C virus
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type peptidase activity
Specific Function
Not Available
Gene Name
NS3/4A
Uniprot ID
B0B3C9
Uniprot Name
Genome polyprotein
Molecular Weight
72789.28 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da

Drug created on October 20, 2016 15:12 / Updated on October 21, 2017 19:35